Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting

被引:197
|
作者
Richardson, Paul G. [1 ]
San Miguel, Jesus F. [2 ,3 ]
Moreau, Philippe [4 ]
Hajek, Roman [5 ]
Dimopoulos, Meletios A. [6 ]
Laubach, Jacob P. [1 ]
Palumbo, Antonio [7 ]
Luptakova, Katarina [7 ]
Romanus, Dorothy [7 ]
Skacel, Tomas [7 ]
Kumar, Shaji K. [8 ]
Anderson, Kenneth C. [1 ]
机构
[1] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA
[2] Clin Univ Navarra, IDISNA, CIMA, Pamplona, Spain
[3] Clin Univ Navarra, CIBERONC, Pamplona, Spain
[4] Univ Hosp Hotel Dieu, Dept Hematol, Nantes, France
[5] Univ Hosp Ostrava, Dept Hematooncol, Ostrava, Czech Republic
[6] Univ Athens, Sch Med, Dept Clin Therapeut, Athens, Greece
[7] Millennium Pharmaceut Inc, Cambridge, MA USA
[8] Mayo Clin, Div Hematol, Rochester, MN USA
来源
BLOOD CANCER JOURNAL | 2018年 / 8卷
关键词
PROGRESSION-FREE SURVIVAL; QUALITY-OF-LIFE; RANDOMIZED CONTROLLED-TRIALS; MINIMAL RESIDUAL DISEASE; PLACEBO PLUS BORTEZOMIB; PHASE-III; NETWORK METAANALYSIS; GERIATRIC ASSESSMENT; CONTINUOUS THERAPY; OPEN-LABEL;
D O I
10.1038/s41408-018-0141-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Substantial improvements in survival have been seen in multiple myeloma (MM) over recent years, associated with the introduction and widespread use of multiple novel agents and regimens, as well as the emerging treatment paradigm of continuous or long-term therapy. However, these therapies and approaches may have limitations in the community setting, associated with toxicity burden, patient burden, and other factors including cost. Consequently, despite improvements in efficacy in the rigorously controlled clinical trials setting, the same results are not always achieved in real-world practice. Furthermore, the large number of different treatment options and regimens under investigation in various MM settings precludes the feasibility of obtaining head-to-head clinical trial data, and there is a temptation to use cross-trial comparisons to evaluate data across regimens. However, multiple aspects, including patient-related, disease-related, and treatment-related factors, can influence clinical trial outcomes and lead to differences between studies that may confound direct comparisons between data. In this review, we explore the various factors requiring attention when evaluating clinical trial data across available agents/regimens, as well as other considerations that may impact the translation of these findings into everyday MM management. We also investigate discrepancies between clinical trial efficacy and real-world effectiveness through a literature review of non-clinical trial data in relapsed/refractory MM on novel agent-based regimens and evaluate these data in the context of phase 3 trial results for recently approved and commonly used regimens. We thereby demonstrate the complexity of interpreting data across clinical studies in MM, as well as between clinical studies and routine-care analyses, with the aim to help clinicians consider all the necessary issues when tailoring individual patients' treatment approaches.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting
    Paul G. Richardson
    Jesus F. San Miguel
    Philippe Moreau
    Roman Hajek
    Meletios A. Dimopoulos
    Jacob P. Laubach
    Antonio Palumbo
    Katarina Luptakova
    Dorothy Romanus
    Tomas Skacel
    Shaji K. Kumar
    Kenneth C. Anderson
    Blood Cancer Journal, 8
  • [2] Translating real-world evidence/real-world data
    Ravenstijn, Paulien
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2024, 17 (05):
  • [3] Real-World or Controlled Clinical Trial Data in Real-World Practice
    Wu, Ting-Hui
    Yang, James Chih-Hsin
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : 470 - 472
  • [4] Evaluating Multiple Myeloma Treatment and Clinical-Decision Making with Real-World Data
    Miller, Jaime
    Walker, Mark
    Assonov, Dmytro
    Chhun, Leena
    O'Brien, Kati
    Blau, C. Anthony
    BLOOD, 2024, 144 : 2384 - 2384
  • [5] Bortezomib therapy in a real-world setting in patients with relapsed or refractory multiple myeloma
    Huang, Shang-Yi
    Chen, Tsai-Yun
    Kuo, Ching-Yuan
    Chen, Yeu-Chin
    Lin, Sheng-Fung
    Chang, Ming-Chih
    Lv, Xinzhu
    Yang, Betty
    Chang, Cheng-Shyong
    ONCOLOGY REVIEWS, 2019, 13 (01) : 15 - 22
  • [6] Treating multiple myeloma in a resource-limited setting: real-world outcomes
    Matinez, Gracia
    Seguro, Fernanda
    Jacomassi, Mayara
    Visnadi, Helena
    Atanazio, Marcelo
    Szor, Roberta
    Neffa, Pedro
    Pereira, Thales
    Silva, Wellington
    Dorlhiac, Pedro
    Velasques, Rodrigo
    Bassoli, Lucas
    Rocha, Vanderson
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S114 - S114
  • [7] Evaluating and interpreting scGPT: A foundation model for singlecell biology in real-world cancer clinical trial data
    Tan, Runzi
    Cui, Haotian
    Wang, Bo
    Perez, Kimberly
    Costa, Andressa Dias
    Jordan, Alexander
    Karacic, Thomas
    Elganainy, Dalia
    Gui, Dan Y.
    Kim, Suryun
    Yuan, Chen
    Truitt, Morgan
    Downes, Michael
    Evans, Ronald
    Oh, Tae Gyu
    O'Dwyer, Peter
    Aguirre, Andrew
    Nowak, Jonathan A.
    Wolpin, Brian
    Cristea, Simona
    CANCER RESEARCH, 2024, 84 (17)
  • [8] Racial Differences in Multiple Myeloma Survival and Treatment Using Pooled Clinical Trial and Real-World Electronic Medical Record Data
    Rusli, Emelly
    Diao, Lihong
    Liu, Cynthia
    Kelkar, Mona A.
    Ensign, Lisa
    Watson, Mark
    Galaznik, Aaron
    BLOOD, 2020, 136
  • [9] Real-World and Clinical Trial Data in Relapsed/Refractory Multiple Myeloma (RRMM): Evaluating Treatment Duration and Comparing Effectiveness and Efficacy
    Richardson, Paul G.
    San Miguel, Jesus F.
    Moreau, Philippe
    Hajek, Roman
    Dimopoulos, Meletios A.
    Palumbo, Antonio
    Luptakova, Katarina
    Skacel, Tomas
    Kumar, Shaji K.
    Anderson, Kenneth C.
    BLOOD, 2017, 130
  • [10] Translating the Lifestyle Interventions and Independence for Elders Clinical Trial to Older Adults in a Real-World Community-Based Setting
    Reid, Kieran F.
    Laussen, Jonathan
    Bhatia, Karan
    Englund, Davis A.
    Kirn, Dylan R.
    Price, Lori Lyn
    Manini, Todd M.
    Liu, Christine K.
    Kowaleski, Christopher
    Fielding, Roger A.
    JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES, 2019, 74 (06): : 924 - 928